PMS-Pantoprazole · DIN 02307871 · 40 mg · enteric-coated tablet
Limited Use, Reason for Use code 293, 295, 297, 401, 402 requiredMarketed · checked November 18, 2026
StatusLimited Use, Reason for Use code 293, 295, 297, 401, 402 required
Write on scriptone applicable Reason for Use code, 293 or 295 or 297 or 401 or 402 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 293, 295, 297, 401, 402
Reason for Use code 293
Gastroesophageal Reflux Disease (GERD)
For the treatment of erosive GERD or upper GI malignancy; OR
For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy.
Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 295
H. pylori-positive Peptic Ulcers
For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy.
Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment).
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 297
Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis:
For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR
For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 401
Other Gastrointestinal Disorders:
For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis.
Note: There is a lack of published evidence to support double-dose PPI therapy in these settings.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 402
Severe Conditions:
For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed.
For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Pantoprazole · DIN 02307871
Manufacturer: Pharmascience Inc.; listing date 2008-08-28
Health Canada: Marketed since 2008-06-04 · brand PMS-PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 40 MG · company Pharmascience inc · schedule Prescription
PMS-Pantoprazole: Formulary list price $0.20 per unit (the source does not state the unit; exact figure $0.2016). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02307871)
Source record
DIN 02307871: PMS-Pantoprazole
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 564000080; group id 694; item number 1716; lccId 00106; manufacturer id PMS
Source form: Ent Tab; strength: 40mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2016; ministry $0.2016
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02307871
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79355
Interchangeable products
AG-Pantoprazole Sodium · DIN 02481588 · $0.2016
Apo-Pantoprazole · DIN 02292920 · $0.2016
Auro-Pantoprazole · DIN 02415208 · $0.2016
Bio-Pantoprazole · DIN 02445867 · $0.2016
Co Pantoprazole · DIN 02300486 · $0.2016
Jamp Pantoprazole Sodium · DIN 02392623 · $0.2016
Jamp-Pantoprazole · DIN 02357054 · $0.2016
M-Pantoprazole · DIN 02467372 · $0.2016
Mar-Pantoprazole · DIN 02416565 · $0.2016
Mint-Pantoprazole · DIN 02417448 · $0.2016
NRA-Pantoprazole · DIN 02471825 · $0.2016
Pantoloc · DIN 02229453 · $0.2016
Pantoprazole · DIN 02370808 · $0.2016
Pantoprazole · DIN 02428180 · $0.2016
Pantoprazole · DIN 02431327 · $0.2016
Pantoprazole · DIN 02547368 · $0.2016
Ran-Pantoprazole · DIN 02305046 · $0.2016
Sandoz Pantoprazole · DIN 02301083 · $0.2016
Teva-Pantoprazole · DIN 02285487 · $0.2016
Shortage status: not checked (no credentials)